Utilization of hepatitis B virus-positive allografts in liver transplantation:a new arrow to the bowstring for expanding the donor pool?  

作　　者：Gang Xu Chen-Hao Jiang Yao Xiao Tao Lyu Li Jiang Lyu-Nan Yan Jia-Yin Yang 

机构地区：[1]Department of Liver Surgery and Liver Transplant Center,Organ Transplant Center,West China Hospital of Sichuan University,Chengdu,China [2]Division of Transplant Surgery,Department of Surgery and Transplant Surgery Research Laboratory,Brigham and Women’s Hospital,Harvard Medical School,Boston,MA,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2022年第2期283-287,共5页肝胆外科与营养（英文）

基　　金：supported by the Sichuan Science and Technology Program(2019YFG0036);the Major National Science and Technology Special Projects(No.2017ZX10203205-005-002 and No.2017ZX10203205-001-004);the National Natural Science Foundation of China(No.81470037 and No.81770653).

摘　　要：Liver disease accounts for approximately 2 million deaths per year worldwide,including 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma(HCC)(1).Liver transplantation(LTx)is the definitive management for end-stage liver disease and HCC in both children and adults.However,the number of liver transplant candidates on the waiting list exceeds that of available allografts.Approximately one-third of the global population has serological evidence of past or current hepatitis B virus(HBV)infection,including 250 million people with chronic HBV infection.The concept of using HBV-positive liver allografts has been implemented to expand the organ pool worldwide(2).Especially in regions with high or intermediate prevalence of HBV infection,these allografts can be an optimal choice for LTx recipients.Over the decades,LTx from HBV-exposed allografts has shifted from the first case in the 1980s to expanded practice supported by positive outcomes,particularly with the availability of safe and effective clinical therapies(3).

关 键 词：ALLOGRAFT string DONOR 

分 类 号：R73[医药卫生—肿瘤]